BioSpace News Archive

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2020 and updated its full year 2020 guidance

First of multiple anticipated milestone payments related to the development of Oral KORSUVA™

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its third quarter 2020 financial results after the market closes on Tuesday, November 10, 2020.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2020. Third Quarter 2020 Financial Highlights: Revenue grew 26% versus the same quarter of the prior year to $500.9 million U.S. revenue growth of 29% and international revenue growth of 17% GAAP operating income of $94.1 million or 18.8% of revenue, an increase of 470 basis points comp

Invacare Corporation (“Invacare”)(NYSE: IVC), a leading manufacturer and distributor of medical equipment used in non-acute care settings, has been recognized by HME Business magazine in multiple product categories for outstanding product development achievements

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced it intends to offer and sell, subject to market and other conditions, $250 million of shares of its common stock in an underwritten public offering.

PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2020.

At Health Canada’s request, LEO Pharma Inc. is withdrawing Picato from the Canadian market.

The United States Preventive Services Task Force (USPSTF) today released draft updated colorectal cancer screening guidelines recommending that screening begin at age 45, and including Exact Sciences’ (NASDAQ: EXAS) Cologuard® (referred to in the draft guidelines as sDNA-FIT) as a recommended screening method for all average-risk patients between the ages of 45 and 75.